Subtitle
Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database.
Subtitle
Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database.
Proto therapy Time
November 2022
Executive summary
With the data from the National Cancer Database, this study investigated the utilization pattern and outcomes of IMRT, brachytherapy (BT), PT and SBRT for localized prostate cancer stratified by risk group. The most utilized treatment modality for all PCa patients was IMRT (53.1%). Over the years, a steady increase in SBRT utilization was observed, whereas BT HDR usage declined. IMRT-treated patient groups exhibited relatively lower survival probability in all risk categories. BT, SBRT, and IMRT+BT exhibited similar survival rates. A slightly better survival probability was observed for the PT group across all risk groups.
Key content topics
Related contents
Proton Therapy Publication
November 2020
Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
Proton Therapy Publication
October 2023
Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Proton Therapy Publication
December 2023
Comparison of the Effectiveness of Radiotherapy with 3D-CRT, IMRT, VMAT and PT for Newly Diagnosed Glioblastoma: A Bayesian Network Meta-Analysis.
Proton Therapy Publication
July 2023
Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience.
Proton Therapy Publication
August 2022
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
Proton Therapy Publication
October 2022
High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Proton Therapy Publication
October 2022
Systematic Review for Deep Inspiration Breath Hold in Proton Therapy for Mediastinal Lymphoma: A PTCOG Lymphoma Subcommittee Report and Recommendations.
Proton Therapy Publication
November 2022
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.